SKAN Group AG
SIX:SKAN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
70.8
85.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SKAN Group AG
SKAN Group AG
Cost of Revenue
SKAN Group AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SKAN Group AG
SIX:SKAN
|
Cost of Revenue
-CHf79.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-456%
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Cost of Revenue
-CHf398.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Cost of Revenue
-CHf952.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Cost of Revenue
-CHf4.7B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
Tecan Group AG
SIX:TECN
|
Cost of Revenue
-CHf653.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Cost of Revenue
-€315.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
SKAN Group AG
Glance View
SKAN Group AG engages in the development, design, and manufacture of process isolators for the aseptic filling of biopharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2007-04-05. The company concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The firm acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.
See Also
What is SKAN Group AG's Cost of Revenue?
Cost of Revenue
-79.5m
CHF
Based on the financial report for Dec 31, 2023, SKAN Group AG's Cost of Revenue amounts to -79.5m CHF.
What is SKAN Group AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-456%
Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for SKAN Group AG have been -11% over the past three years , -456% over the past five years .
You don't have any saved screeners yet
